Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN LA versus SYNAREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN LA versus SYNAREL.
SUPPRELIN LA vs SYNAREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Binds to pituitary GnRH receptors, initially stimulating then desensitizing them, leading to suppressed LH and FSH secretion, decreased gonadal steroid production (estrogen, testosterone).
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
200 mcg intranasally twice daily (400 mcg total daily dose) for 6 months. Initiate on day 5 of menstural cycle.
None Documented
None Documented
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Terminal elimination half-life: ~3 hours (range 2-5 hours) after intranasal administration; clinically, dosing every 12 hours maintains therapeutic levels.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Renal: ~90% as parent drug and metabolites; fecal: <10%.
Category C
Category C
GnRH Agonist
GnRH Agonist